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Clostridium difficile infection (CDI) is primarily associated with hospitalised patients, 
however, community-associated CDI (CA-CDI) has increased in Australia. We aimed to 
investigate the epidemiology and outcomes of CA-CDI cases presenting to hospital 
emergency departments in Western Australia (WA). A retrospective case-control study of 
CA-CDI cases presenting at six emergency departments in WA from July 2013 to June 2014 
was performed. Clinical signs, recent medication, hospitalisations and potential risk factors 
for CA-CDI were investigated for cases (n=34) and unmatched controls (n=62) who were 
infected with another gastrointestinal pathogen, including Campylobacter spp., Salmonella 
spp., Aeromonas spp., Shigella sonnei and Escherichia coli O157. Elevated white cell count 
(31.3% vs 8.2%, p<0.01), female gender (67.6% vs 41.9%, p<0.05), age 65 years (41.2% vs 
21.0%, p<0.05) and antimicrobial use in the previous month (41.2% vs 11.3%, p<0.01) were 
significantly more frequent among cases compared to controls. After multivariable analysis, 
antibiotic use (odds ratio 8.49, 95% confidence interval 2.75-26.21) and age 65 years (3.03, 
1.05-8.75) were significantly associated with CA-CDI. Ribotype (RT) 014/020 was most 
common (40.7%) among 27 C. difficile isolates followed by RTs 002 (14.8%), 001, 056 and 
244 (all 7.4%).  
CA-CDI was associated with advanced age and recent antibiotic use compared to those 
infected with other gastrointestinal pathogens. RT 014 has also recently been found at high 
prevalence in public lawn spaces, and previously RT 014 strains from humans and pigs in 
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Introduction 
Over recent decades, major outbreaks of Clostridium difficile infection (CDI) have occurred 
in North America and Europe (1). C. difficile produces spores highly resistant to disinfection 
which, coupled with increasing rates of antibiotic usage worldwide, have contributed to it 
becoming one of the most common causes of nosocomial infection in developed countries 
(1), primarily in older patients with recent antimicrobial exposure. The most notable 
emergence of C. difficile to date was associated with a particular strain, ribotype (RT) 027. 
This fluoroquinolone-resistant, binary toxin (CDT)-producing strain has caused significant 
outbreaks in North America and Europe since the 2000s, and persisted ever since, particularly 
in the USA (2).  
More recently, community-associated CDI (CA-CDI), where no hospitalisation has occurred 
in the previous 12 weeks (3), has been reported increasingly from many regions, representing 
proportions from 14% to 30% of all CDI in North America (4) and Europe (5). Patients with 
CA-CDI were younger and had fewer comorbidities than patients with healthcare facility-
associated CDI (HA-CDI) (4).  
The incidence of CDI in Australia increased recently, with 26% of cases thought to be CA-
CDI (6). A strain of C. difficile with similarities to the epidemic RT 027 strain, RT 244, 
emerged in Australia in 2011 (7). RT 244 strains produced CDT but, unlike RT 027, were 
susceptible to fluoroquinolones (8). RT 244 has been associated with poor outcomes; a 30-
day mortality of 42% was estimated in a case-control study in Melbourne (8) and increased 
mortality was reported in RT 244 cases in New Zealand (9). RT 244 infection was primarily 
seen in CA-CDI cases, and more broadly among CDI cases with onset of symptoms in the 
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community, suggesting a reservoir of infection outside hospitals. Whole genome sequencing 
of isolates from across Australia revealed close genetic relatedness between isolates despite 
geographic separation of many thousands of kilometres, further implying a clonal reservoir of 
infection across Australia and New Zealand (7). 
The increase in CA-CDI incidence and emergence of strains causing severe disease among 
non-hospitalised patients highlighted the need for investigation of CDI within the community 
in Australia. The epidemiology of CA-CDI in Australia has not been studied extensively to 
date, but 50.8% of all CDI cases in Western Australia (WA) in July 2014 had onset of 
symptoms in the community, regardless of acquisition in the community or a healthcare 
facility (10). We aimed to describe the epidemiology of CA-CDI among patients at 
emergency departments in WA, and compare cases with emergency department patients 
presenting with diarrhoea due to other gastrointestinal pathogens, in order to assess the 
specific risk factors and outcomes associated with CDI in the community.  
Methods 
Study setting and design 
A case-control study was performed across six hospital emergency departments in WA; five 
in the Perth Metropolitan area and one regional hospital in the South West of the State. 
Faecal specimens were collected from patients 18 years of age presenting to emergency 
departments with diarrhoea (loose or watery stool, assuming its container’s shape) from July 
2013 to June 2014 and were processed routinely in local diagnostic laboratories, where an 
array of tests for bacterial pathogens was performed. Cases were defined as all patients 
presenting to an emergency department with diarrhoea, confirmed as having C. difficile by 
tcdB PCR using the BD MAX™ platform (BD Diagnostics, Franklin Lakes, NJ, USA), and 
fulfilling the definition of CA-CDI (see below), during the study period. A subset of controls, 
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who had diarrhoea and were diagnosed with a bacterial pathogen other than C. difficile, were 
selected randomly from a subset of patients presenting to five of the six emergency 
departments. Utilising controls who also presented to emergency department with diarrhoea 
and submitted a faecal sample reduces potential confounding due to differences in health care 
seeking behaviour. 
Data collection 
The emergency department medical record of cases and controls was reviewed to collect 
information on age, sex, medication use over the previous month and clinical findings during 
their presentation. If patients were admitted to the hospital for further treatment, information 
on treatments and outcomes was collected from their admitted patient records. 
Microbiological analysis 
C. difficile tcdB-positive faecal specimens were cultured on ChromID™ C. difficile agar 
(bioMerieux, Marcy l’Etoile, France) and isolates identified as previously described (10). 
DNA was extracted from pure cultures on blood agar plates and PCR detection of the toxin 
genes tcdA, tcdB, cdtA and cdtB and PCR ribotyping was performed as previously described 
(11), assigning internationally recognised RT numbers, or a local nomenclature prefixed by 
“QX”.  
Data analysis 
Medical chart review information was collected in EpiInfo 7™ (CDC, Atlanta). SPSS® 
Statistics version 22.0 (IBM, Zurich) was used to merge patient laboratory results with 
corresponding chart review data, and for statistical analysis. 
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CA-CDI was defined as CDI in a patient with no history of hospital admission within the past 
12 weeks. HA-CDI was defined as a CDI case who was hospitalised in the previous 4 weeks. 
Cases were defined as “indeterminate” where a case had been hospitalised in the previous 4-
12 weeks (3). Recurrent CDI was defined as an episode of CDI occurring within 8 weeks 
after a previous, resolved episode. A history of CDI was defined as a resolved episode of CDI 
occurring > 8 weeks previous to the current episode. 
Descriptive analyses of characteristics of patients were performed comparing proportions by 
χ2 test between cases and controls. Medians were compared using the Mann Whitney U test. 
Risk factors for CA-CDI, comparing CA-CDI cases with controls, were determined by 
calculating univariable odds ratios (ORs) with 95% confidence intervals (CIs) and two-sided 
p values. A multivariable backwards stepwise logistic regression analysis was performed 
including variables where the univariable OR suggested an association (p<0.2), excluding 
variables where n<5. 
Ethical approval 
Ethical approval with a waiver of consent was granted by the Sir Charles Gairdner Group 
Human Research Ethics Committee (HREC) (#2012-185) with site approvals from the 
participating hospital HRECs and Research Governance units, as well as The University of 
Western Australia HREC (#RA/4/1/6130) and the Curtin University HREC (#HR 52/2013).  
Results 
During the 1 year study period, total 77 CDI cases presented across the six emergency 
departments, of which 34 (44.2%) were classified as CA-CDI and 38 (49.1%) were HA-CDI; 
another 2 cases (2.9%) were of indeterminate association while details of previous 
hospitalisations could not be obtained for 3 cases. Data were collected for all CA-CDI cases 
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and 62 controls with another gastrointestinal pathogen isolated, namely Campylobacter spp. 
(n=44), Salmonella spp. (n=11), Aeromonas spp. (n=4), Shigella sonnei (n=2) and 
Escherichia coli O157 (n=1). 
Characteristics of cases and controls at emergency departments are shown in Table 1. CDI 
cases were more commonly female (67.6% vs 41.9%, p<0.05) compared to controls. The age 
distribution of cases differed from controls; the majority of controls were aged <35 y 
(48.4%), while the majority of cases were aged  65 y (41.2%). Abdominal pain was more 
frequently seen among controls than cases (44.1% vs 77.4%, p<0.01). Fever (temperature 
38°C) did not differ between groups (32.4% vs 38.7%). Elevated white cell count (WCC; 
15,000 cells/µL, 31.3% vs 8.2%, p<0.01) and hypertension (11.8% vs 3.2%) on arrival were 
significantly more frequent among cases (Table 1).  
The most common comorbidity among patients was hypertension, evenly distributed among 
23.5% of cases and 22.6% of controls. GORD was less frequent among cases than controls 
(8.8% vs 16.1%), diabetes was more frequent among cases (11.8% vs 8.1%) and solid 
tumours were also more frequent among cases (8.8% vs 4.8%, Table 1); none of these 
differences was statistically significant. 
The most commonly used medication in cases was antibiotics (41.2% cases vs 11.3% 
controls, p<0.01). Proton pump inhibitors (PPIs, 23.5% vs 25.8%) were used by a similar 
proportion of cases and controls. Where the class of antibiotic was recorded, cephalosporins 
(15.6% vs 3.3% in controls, p<0.05) were most frequently used, followed by amoxycillin 
(12.5% vs 0%, p<0.01) and fluoroquinolones (3.1% and 5.0%). Steroids were also more 
frequently used by cases (14.7% vs 3.2%, p<0.05, Table 1). No cases experienced 
complications such as toxic megacolon or pseudomembranous colitis, and no cases or 
controls were deceased after 30 days. 
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Comparing cases with controls by univariable analysis, antibiotic use was most significantly 
associated with CA-CDI (OR 5.50, 95% CI 1.94-15.59, p<0.01). Female gender and age  65 
years were also associated with CA-CDI (ORs 2.90 [1.20-6.97] and 2.64 [1.06-6.60]) (Table 
2). After multivariable analysis, only age  65 y (OR 3.03 [1.05-8.75] and antibiotic use (OR 
8.49 [2.75-26.21]) were significantly associated with CA-CDI. 
C. difficile isolates were recovered for 27 cases. RT 014/020 was the most common RT 
(n=11; 40.7%), followed by RT 002 (n=4; 14.8%), and RTs 001, 056 and 244 (all n=2; 
7.4%). Three isolates were CDT-positive, two of which were RT 244, and one RT 078 (Table 
3). 
Discussion 
CA-CDI continues to increase around the world (4, 5). In Australia, increases in CA-CDI 
have also been observed recently (6) prompting our study of emergency department 
presentations with diarrhoea at WA hospitals. We found a number of similarities with the 
results of studies elsewhere in the world. A substantial proportion of CDI cases (44.2%) 
presenting at WA emergency departments were CA-CDI, and CA-CDI cases were 
predominantly caused by RT 014/020 C. difficile (40.7%). CA-CDI cases were more likely 
than controls to be of advanced age and to have used antibiotics, both known primary risk 
factors for CDI (1).  In the US, the greatest increase in rising CDI rates in emergency 
department patients occurred in patients aged 18-24 years, however the greatest proportion of 
cases overall was in the 65 year age group (12). Similarly, in our study the greatest 
proportion of all cases was aged 65 years (48.1%), however, a substantial proportion of CA-
CDI cases were aged 18-35 years (35.3%). The proportion of CA-CDI found here (44.2%) 
mirrors a Canadian study where 44% of CDI cases in emergency departments were CA-CDI 
(13). A study in Taipei found that emergency department CDI cases more often occurred in 
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warm spring and summer seasons (14). In the present study, cases also peaked in the summer 
months (data not shown) although the significance of this finding or reasons for it is not 
apparent. Peaks in overall CDI rates in the summer months were also previously observed in 
2011/2012 in WA, with a particular peak in cases caused by RT 244, discussed below (7).  
 
It is interesting to note the predominance of RT 014/020 strains among CA-CDI cases in this 
study (40.7%, Table 3). RT 014/020 is consistently the most common strain isolated in CDI 
cases in Australia (11). This RT is also highly prevalent in Australian pigs (15). Genomic 
analysis of C. difficile RT 014 strains isolated from humans and pigs across Australia showed 
high clonality among some strains despite long-range geographic separation, suggesting 
either a common source of exposure or transmission of the strains between the two species 
(16). This finding suggests that C. difficile could potentially enter the human food chain via 
contamination of food, either meat or meat products or root vegetables, which are fertilised 
with manure from production animals. We have isolated C. difficile from root vegetables and 
gardening products in the Perth Metropolitan region (17, 18), and found an overall prevalence 
of C. difficile of 59% in 311 local public lawn space samples (19).  RT 014/020 also 
predominated in lawns with 39% of isolates belonging to this RT, thus lawn spaces are likely 
a reservoir of CA-CDI in WA. 
 
The presence of CDT-positive RT 244 was also notable, having caused widespread outbreaks 
across Australia in the summer of 2011/2012 with an apparent common, as yet unidentified, 
source (7).  The two cases with RT 244 infection in this study presented two months apart at 
two different hospitals. Given that patients here presented at emergency departments with RT 
244 infection in 2013/14, a reservoir in the community may still exist. Otherwise, a single RT 
078 strain, also CDT-positive, was also isolated. Since RT 078 is rarely identified in 
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Australia (11), it may possibly have been acquired during overseas travel. We were unable to 
obtain any travel history for the case.  However, RT 078 is highly prevalent in production 
animals in the Northern Hemisphere (20, 21), has been shown to contaminate food (23, 24), 
and is a common cause of human infection (5).  Thus RT 078 may have entered Australia on 
imported food, the most likely culprit being pork. 
 
This study has some limitations. We had limited access to emergency department patient 
information so we were unable to calculate the prevalence or incidence rates of CA-CDI 
among emergency department patients. Thus cases were compared with unmatched controls 
randomly selected from available information from a subset of hospitals, which may have 
biased our results. Another limitation was the requirement for a stool sample from emergency 
department patients. All patients presenting to emergency departments with diarrhoea were 
asked to provide a stool sample during the study period, however, many patients may not 
have provided one during their emergency department visit. Those experiencing more severe 
symptoms may have been more likely to produce a sample, which could have introduced a 
bias in our results regarding severity. However, this would not differ between cases and 
controls. Also, patients who were recently hospitalised may have been more likely to seek 
further hospital care.  
Despite limitations the study highlighted that patients in the community are exposed to and 
infected with C. difficile strains which are known to cause severe CDI. The sources of these 
strains need to be investigated in further detail, as well as identifying risk factors for CA-CDI 
specifically. Further studies should employ highly discriminatory techniques including whole 
genome sequencing to compare CA-CDI strains with environmental, animal and food strains 
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Table 1. Characteristics of diarrhoeal patients with CA-CDI (cases) or infection with another 
gastrointestinal bacterial pathogen (controls) on emergency department presentation. 
Characteristic  Cases (n=34) Controls (n=62) Total (N=96) 
    
Female 23 (67.6) 26 (41.9)* 49 (51.0) 
Age group    
 18-34 y 12 (35.3) 30 (48.4) 42 (43.8) 
 35 - 49 y 4 (11.8) 9 (14.5) 13 (13.5) 
 50 - 64 y 4 (11.8) 10 (16.1) 14 (14.6) 
  65 y 14 (41.2) 13 (21.0)* 27 (28.1) 
emergency department presentation    
History of CDI 5 (14.7) 2 (3.2)* 7 (7.3) 
 Abdominal pain 15 (44.1) 48 (77.4)** 63 (65.6) 
 Hypertension 4 (11.8) 2 (3.2) 6 (6.3) 
 Hypotension 1 (2.9) 1 (1.6) 2 (2.1) 
 Fever (38°C) 11 (32.4) 24 (38.7) 35 (36.5) 
 Elevated white cell count 10 (31.3) 5 (8.2)** 15 (16.1) 
Comorbidities    
 Inflammatory bowel disease 2 (5.9) 1 (1.6) 3 (3.1) 
 Hypertension 8 (23.5) 14 (22.6) 22 (22.9) 
 Diabetes 4 (11.8) 5 (8.1) 9 (9.4) 
 Solid tumour 3 (8.8) 3 (4.8) 6 (6.3) 
 Leukaemia 1 (2.9) 1 (1.6) 2 (2.1) 
 GORD 3 (8.8) 10 (16.1) 13 (13.5) 
 Myocardial infarction 1 (2.9) 1 (1.6) 2 (2.1) 
 Peptic ulcer 1 (2.9) 4 (6.5) 5 (5.2) 
 COPD 1 (2.9) 1 (1.6) 2 (2.1) 
 Liver disease 3 (8.8) 1 (1.6) 4 (4.2) 
 Renal disease 3 (8.8) 1 (1.6) 4 (4.2) 
 Cerebrovascular disease 1 (2.9) 0 1 (1.0) 
 Congestive heart failure 1 (2.9) 0 1 (1.0) 
 Connective tissue disease 1 (2.9) 1 (1.6) 2 (2.1) 
 Peripheral vascular disease 2 (5.9) 0 2 (2.1) 
Previous medication    
 Steroid 5 (14.7) 2 (3.2)* 7 (7.3) 
 PPI 8 (23.5) 16 (25.8) 24 (25.0) 
 H2RA 0 2 (3.2) 2 (2.1) 
 Probiotic 0 2 (3.2) 2 (2.1) 
 Chemotherapy 3 (8.8) 2 (3.2) 5 (5.2) 
 Antibiotic 14 (41.2) 7 (11.3)** 21 (21.9 ) 
 Cephalosporin 5 (15.6) 2 (3.3)* 7 (7.6) 
 Amoxycillin/amoxycillin clavulanate 4 (12.5) 0** 4 (4.3) 
 Metronidazole 1 (3.1) 0 1 (1.1) 
 Trimethoprim/sulfamethoxazole 2 (6.3) 0 2 (2.2) 
 Fluoroquinolone 1 (3.1) 3 (5.0) 4 (4.3) 
 Laxative 3 (8.8) 2 (3.2) 5 (5.2) 





GORD, gastro-oesophageal reflux disease; COPD, chronic obstructive pulmonary disease; PPI, proton 
pump inhibitor; H2RA, H2 receptor agonist  
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Table 2. Risk factor analysis for CA-CDI cases compared with controls. 
Characteristic  Univariable OR 
(95% CI) 
p Multivariable OR 
(95% CI)  
p 
Female 2.90 (1.20-6.97) 0.02   
Age group     
 18-34 y 0.58 (0.25-1.38) 0.22   
 35 - 49 y 0.79 (0.22-2.77) 0.70   
 50 - 64 y 0.69 (0.20-2.40) 0.56   
  65 y 2.64 (1.06-6.60) 0.04 3.03 (1.05-8.75) 0.04 
History of CDI 5.17 (0.05-28.28) 0.06   
Comorbidities     
 Inflammatory bowel 
disease 
3.81 (0.33-43.67) 0.28   
 Hypertension 1.06 (0.39-2.84) 0.92   
 Diabetes 1.52 (0.38-6.09) 0.55   
 Solid tumour 1.90 (0.36-9.99) 0.45   
 Leukaemia 1.85 (0.11-30.52) 0.67   
 GORD 0.50 (0.13-1.97) 0.32   
 Myocardial infarction 1.85 (0.11-30.52) 0.67   
 Peptic ulcer 0.44 (0.05-4.10) 0.47   
 COPD 1.85 (0.11-30.52) 0.67   
 Liver disease 5.90 (0.59-59.12) 0.13   
 Renal disease 5.90 (0.59-59.12) 0.13   
 Connective tissue disease 1.85 (0.11-30.52) 0.67   
Previous medication     
 Steroid 5.17 (0.95-28.28) 0.06 6.01 (0.99-36.68) 0.05 
 PPI 0.89 (0.33-2.35) 0.81   
 Chemotherapy 2.90 (0.46-18.30) 0.26   
 Antibiotic 5.50 (1.94-15.59) 0.001 8.49 (2.75-26.21) <0.001 
 Laxative 2.90 (0.46-18.30) 0.26   
     
 
OR: Odds ratio; CI: Confidence interval  
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Table 3. Molecular characteristics of C. difficile isolates from emergency department 
presentations with CA-CDI. 
RT Toxin profile CA-CDI   
   
014/020 A+B+CDT- 11 (40.7) 
002 A+B+CDT- 4 (14.8) 
001 A+B+CDT- 2 (7.4) 
056 A+B+CDT- 2 (7.4) 
244 A+B+CDT+ 2 (7.4) 
005 A+B+CDT- 1 (3.7) 
015 A+B+CDT- 1 (3.7) 
081 A+B+CDT- 1 (3.7) 
QX 013 A+B+CDT- 1 (3.7) 
010* A-B-CDT- 1 (3.7) 
078 A+B+CDT+ 1 (3.7) 
Total  27 (100.0) 
 
*non-toxigenic strain likely to be carried with toxigenic strain not isolated by culture. 
 
 
 
